Hybrid CDMO-gene therapy developer Forge launches with $40M

With $40 million from an investor group led by Chris Garabedian’s PXV fund, newly launched Forge Biologics is building a hybrid company that will offer CDMO services to gene therapy companies while also developing its own pipeline, including a lead program for Krabbe disease.

Housed in an existing facility called the Hearth in Columbus, Ohio, Forge is adding capacity and technology that the company believes will allow it to provide cGMP manufacturing services to adeno-associated viral (AAV) vector gene therapy companies by mid-2021...